SynthesisNutrients2024
Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review.
Synthesis in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 6 citations in OpenAlex.
- Skeletal and body composition effects of orchiectomy in a colony of diet-induced obese cynomolgus macaques.JBMR plus · 2026Article
- The role of the prognostic nutritional index at baseline and follow-up in patients with metastatic prostate cancer.Discover oncology · 2026Article
- Muscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy.Nature communications · 2026Article
- MRI evaluation of obturator internus muscle: its relationship with body composition and prognostic implications in prostate cancer patients undergoing ADT.European radiology · 2026Article
- Review
- Review
- Intermittent Fasting and Androgen Receptor Signaling in Prostate Cancer: Metabolic Crosstalk and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Paradoxical Effect of Obesity on Survival Outcomes in Prostate Cancer Patients Receiving Enzalutamide and Abiraterone.Medicina (Kaunas, Lithuania) · 2026Article
- Role of Tumor Microenvironment in Prostate Cancer Immunometabolism.Biomolecules · 2025Review
- Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The changes in body composition during androgen deprivation therapy (ADT) in patients suffering from prostate cancer (PCa) are recognized by professionals more often as biomarker for effective treatment. The aim of this study was to investigate the impact of ADT on the sarcopenia development in PCa. The following databases were used: PubMed, Embase, Web of Science and Scopus databases. Out of 2183 studies, 7 were included in this review. The fixed-effect model was used in the meta-analysis. A significant increase in SATI (Subcutaneous Adipose Tissue Index) of 0.32 (95% CI: 0.13-0.51)
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.